Who founded Ocular Therapeutix Nasdocul?

Ocular Therapeutix Nasdocul was founded by Amarpreet Sawhney in 2006.

Who are Ocular Therapeutix Nasdocul's investors?

Ocular Therapeutix Nasdocul's investors include Ascension Ventures, Sofinnova Ventures, SV Health Investors, Top Corner Capital, Agent Capital.

How much funding has Ocular Therapeutix Nasdocul raised?

Ocular Therapeutix Nasdocul has disclosed $37.5M raised across 1 round.

Where is Ocular Therapeutix Nasdocul headquartered?

Ocular Therapeutix Nasdocul is headquartered in Bedford, US.

Ocular Therapeutix Nasdocul

Bedford, US · Founded 2006 · 359 employees on LinkedIn · 5 known investors

Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Ocular Therapeutix Nasdocul was founded in 2006 by Amarpreet Sawhney.

Amarpreet SawhneyFounder

Kevin HanleyExecutive

Michael GoldsteininChief Strategy Advisor2022–2023

Daniel BollagExecutive

Antony MattessichinPresident and CEO2017–2024

Donald NotmaninChief Operating Officer and Chief Financial Officer

Pravin U. Dugel, MDExecutive Chairman, President, and CEO

Jeffrey S. Heier, MDChief Scientific Officer

Nadia K. Waheed, MD, MPHChief Medical Officer

Peter K. Kaiser, MDChief Development Officer

Pravin DugelinExecutive Chairman, President, and CEO

Board

Charles WardenBoard director

Investors · 5

Ascension VenturesSaint Louis · $10M – $20M

Sofinnova VenturesMenlo Park · $100K – $15M

SV Health InvestorsBoston · $1M – $20Mvia Charles Warden · board

Top Corner CapitalBurlingame

Agent CapitalreportedWalthamvia Bruce Peacock · board

Reported raises · per SEC filings

Form D private placements

$37.5M disclosed across 1 round · 2019

▶$37.5MraisedMar 2019 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

W. James O'SheaDirector
Kevin HanleyExecutive Officer
Richard L. LindstromDirector
Michael GoldsteinExecutive Officer
Amarpreet SawhneyDirector
Daniel BollagExecutive Officer
Jeffrey S. HeierDirector
Antony MattessichExecutive Officer, Director
Donald NotmanExecutive Officer
Jaswinder ChadhaDirector
Charles WardenDirector
Bruce A. PeacockDirector

Offering amount: $37.5M
Amount sold: $37.5M
Finders' fees: $75K
Placement agents: Piper Jaffray & Co.
First sale: Mar 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Ocular Therapeutix Nasdocul do?: Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.
Who founded Ocular Therapeutix Nasdocul?: Ocular Therapeutix Nasdocul was founded by Amarpreet Sawhney in 2006.
Who are Ocular Therapeutix Nasdocul's investors?: Ocular Therapeutix Nasdocul's investors include Ascension Ventures, Sofinnova Ventures, SV Health Investors, Top Corner Capital, Agent Capital.
How much funding has Ocular Therapeutix Nasdocul raised?: Ocular Therapeutix Nasdocul has disclosed $37.5M raised across 1 round.
Where is Ocular Therapeutix Nasdocul headquartered?: Ocular Therapeutix Nasdocul is headquartered in Bedford, US.